# Bevacizumab in Treating Patients With Myelodysplastic Syndrome

> **NCT00022048** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanford University**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00022048
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022048, "Bevacizumab in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00022048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*